1. Expression of Jejunal Taste Receptors in Women with Morbid Obesity
- Author
-
Laia Bertran, Marta Portillo-Carrasquer, Salomé Martínez, Carmen Aguilar, Miguel Lopez-Dupla, David Riesco, Jessica Binetti, Margarita Vives, Fàtima Sabench, Daniel Del Castillo, Cristóbal Richart, and Teresa Auguet
- Subjects
metabolic syndrome ,nonalcoholic fatty liver disease ,taste receptors ,gastrointestinal tract ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Nutrient sensing plays important roles in promoting satiety and maintaining good homeostatic control. Taste receptors (TAS) are located through the gastrointestinal tract, and recent studies have shown they have a relationship with metabolic disorders. The aim of this study was to analyze the jejunal expression of TAS1R2, TAS1R3, TAS2R14 and TAS2R38 in women with morbid obesity, first classified according to metabolic syndrome presence (MetS; n = 24) or absence (non-MetS; n = 45) and then classified according to hepatic histology as normal liver (n = 28) or nonalcoholic fatty liver disease (n = 41). Regarding MetS, we found decreased expression of TAS2R14 in MetS patients. However, when we subclassified patients according to liver histology, we did not find differences between groups. We found negative correlations between glucose levels, triglycerides and MetS with TAS1R3 expression. Moreover, TAS2R14 jejunal expression correlated negatively with the presence of MetS and ghrelin levels and positively with the jejunal Toll-like receptor (TLR)4, peroxisome proliferator-activated receptor (PPAR)-γ, and interleukin (IL)-10 levels. Furthermore, TAS2R38 expression correlated negatively with TLR9 jejunal expression and IL-6 levels and positively with TLR4 levels. Our findings suggest that metabolic dysfunctions such as MetS trigger downregulation of the intestinal TASs. Therefore, taste receptors modulation could be a possible therapeutic target for metabolic disorders.
- Published
- 2021
- Full Text
- View/download PDF